{
    "Clinical Trial ID": "NCT00509587",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Pazopanib Hydrochloride)",
        "  Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  pazopanib hydrochloride: Given orally",
        "  pharmacological study: Correlative studies",
        "  laboratory biomarker analysis: Correlative studies"
    ],
    "Eligibility": [
        "Criteria:",
        "  No prior bevacizumab",
        "  Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)",
        "  Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan",
        "  Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)",
        "  Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin\u00ae) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)",
        "  No known brain metastases",
        "  ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%",
        "  Life expectancy > 12 weeks",
        "  Absolute neutrophil count >= 1,500/mm\u00b3",
        "  Platelets >=100,000/mm\u00b3",
        "  Total bilirubin normal (exception made for patients with known Gilbert's disease)",
        "  AST/ALT =< 2.5 times upper limit of normal (ULN)",
        "  No proteinuria > +1 on two consecutive dipsticks taken >= 1 week apart",
        "  PT/INR/PTT =< 1.2 times ULN",
        "  No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents",
        "  No QTc prolongation (defined as a QTc interval >= 500 msecs) or other significant ECG abnormalities",
        "  No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug",
        "  No poorly controlled hypertension (systolic blood pressure [BP] >= 140 mm Hg or diastolic BP >= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is < 140/90 mm Hg",
        "  No serious or non-healing wound, ulcer, or bone fracture",
        "  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks",
        "  No cerebrovascular accident within the last 6 months",
        "  No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks",
        "  No venous thrombosis within the last 12 weeks",
        "  No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment",
        "  No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery",
        "  No cardiac angioplasty or stenting within the last 12 weeks",
        "  No more than 1 prior chemotherapy regimen for recurrent disease",
        "  No prior surgical procedures affecting absorption",
        "  No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:",
        "  Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed",
        "  No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:",
        "  Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil",
        "  Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine",
        "  Immune modulators: cyclosporine, tacrolimus, or sirolimus",
        "  Miscellaneous: theophylline, quetiapine, or risperidone",
        "  No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:",
        "Oral hypoglycemics: glipizide, glyburide, or tolbutamide",
        "  Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine",
        "  Neuroleptics: pimozide",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients",
        "  No other concurrent investigational agents",
        "  No other concurrent anticancer therapy",
        "  WBC >= 3,000/mm\u00b3",
        "  No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease",
        "  Creatinine normal OR creatinine clearance >= 60 mL/min",
        "  At least 3 months since prior trastuzumab"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Partial and Complete Response.",
        "  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT / MRI: Complete Response (CR), Disappearance of all target lesions\u037e Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions\u037e Overall Response (OR) = CR + PR",
        "  Time frame: Up to 3 years",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Pazopanib Hydrochloride)",
        "  Arm/Group Description: Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  pazopanib hydrochloride: Given orally",
        "  pharmacological study: Correlative studies",
        "  laboratory biomarker analysis: Correlative studies",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Number",
        "  Unit of Measure: participant  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/21 (4.76%)",
        "  Intra abdominal hemorrhage  1/21 (4.76%)",
        "  Esophagitis  1/21 (4.76%)"
    ]
}